Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20 Pt 2):6243s-s6249.

Article  PubMed  Google Scholar 

Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, et al. Bone health in cancer: ESMO Clinical Practice Guidelines†. Ann Oncol. 2020;31(12):1650–63.

Article  CAS  PubMed  Google Scholar 

Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115–7.

Article  PubMed  Google Scholar 

Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American association of oral and maxillofacial surgeons’ position paper on medication-related osteonecrosis of the Jaws-2022 update. J Oral Maxillofac Surg. 2022;80(5):920–43.

Article  PubMed  Google Scholar 

von Moos R, Costa L, Gonzalez-Suarez E, Terpos E, Niepel D, Body JJ. Management of bone health in solid tumours: from bisphosphonates to a monoclonal antibody. Cancer Treat Rev. 2019;76:57–67.

Article  Google Scholar 

D’Oronzo S, Coleman R, Brown J, Silvestris F. Metastatic bone disease: pathogenesis and therapeutic options: Up-date on bone metastasis management. J Bone Oncol. 2019;1(15):100205.

Article  Google Scholar 

World Health Assembly 66. Follow-up to the Political Declaration of the High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases. Report No.: WHA66.10. 2013. https://apps.who.int/iris/handle/10665/150161. Accessed 12 Dec 2022.

Agrasuta V, Thumbuntu T, Karawekpanyawong R, Panichkriangkrai W, Viriyathorn S, Reeponmaha T, et al. Progressive realisation of universal access to oral health services: what evidence is needed? BMJ Glob Health. 2021;6(7):e006556.

Article  PubMed  PubMed Central  Google Scholar 

Marcianò A, Rubino E, Peditto M, Mauceri R, Oteri G. Oral surgical management of bone and soft tissues in MRONJ treatment: a decisional tree. Life (Basel). 2020;10(7):99.

PubMed  Google Scholar 

Moreno-Rabié C, Lapauw L, Gaêta-Araujo H, Ferreira-Leite A, Coucke W, van den Wyngaert T, et al. Radiographic predictors for MRONJ in oncologic patients undergoing tooth extraction. Sci Rep. 2022;4(12):11280.

Article  Google Scholar 

Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol. 2010;136(8):1117–24.

Article  CAS  PubMed  Google Scholar 

McMahon RE, Bouquot JE, Glueck CJ, Griep JA, Adams WR, Spolnik KJ, et al. Staging bisphosphonate-related osteonecrosis of the jaw should include early stages of disease. J Oral Maxillofac Surg. 2007;65(9):1899–900.

Article  PubMed  Google Scholar 

Bedogni A, Fusco V, Agrillo A, Campisi G. Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ). Oral Dis. 2012;18(6):621–3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Japanese Allied Committee on Osteonecrosis of the Jaw, Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, et al. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab. 2017;35(1):6–19.

Article  Google Scholar 

Caminha RDG, Alcantara PL, Carvalho CG, Reia VCB, Capelozza ALA, da Santos PSS. The impact of medication-related osteonecrosis of the jaws on the quality of life in cancer patients. J Clin Exp Dent. 2020;12(8):e725-9.

Article  PubMed  PubMed Central  Google Scholar 

Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw–2014 update. J Oral Maxillofac Surg. 2014;72(10):1938–56.

Article  PubMed  Google Scholar 

AlRowis R, Aldawood A, AlOtaibi M, Alnasser E, AlSaif I, Aljaber A, et al. Medication-Related Osteonecrosis of the Jaw (MRONJ): a review of pathophysiology, risk factors, preventive measures and treatment strategies. Saudi Dent J. 2022;34(3):202–10.

Article  PubMed  PubMed Central  Google Scholar 

Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(1):60–72.

Article  CAS  PubMed  Google Scholar 

Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws–2009 update. J Oral Maxillofac Surg. 2009;67(5 Suppl):2–12.

PubMed  Google Scholar 

Coleman RE, Collinson M, Gregory W, Marshall H, Bell R, Dodwell D, et al. Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04). J Bone Oncol. 2018;13:123–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679–91.

Article  CAS  PubMed  Google Scholar 

Kizub DA, Miao J, Schubert MM, Paterson AHG, Clemons M, Dees EC, et al. Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307). Support Care Cancer. 2021;29(5):2509–17.

Article  PubMed  Google Scholar 

Paterson AHG, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol. 2012;13(7):734–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Valachis A, Polyzos NP, Coleman RE, Gnant M, Eidtmann H, Brufsky AM, et al. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist. 2013;18(4):353–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vidula N, Greenberg S, Petrillo L, Hwang J, Melisko M, Goga A, et al. Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid. NPJ Breast Cancer. 2021;7(1):113.

Article  CAS  PubMed  PubMed Central  Google Scholar 

von Minckwitz G, Möbus V, Schneeweiss A, Huober J, Thomssen C, Untch M, et al. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol. 2013;31(28):3531–9.

Article  Google Scholar 

Fusco V, Alessio M, Guglielmini PF, Vincenti M, Fasciolo A, Rossi M. Is Medication-Related Osteonecrosis of the Jaws (MRONJ) Associated to Cyclin-Dependent Kinase (CDK) 4/6 inhibitors? A Word of Cautiousness. Comment on Marcianò et al. medication-related osteonecrosis of the jaws and CDK4/6 Inhibitors: a recent association. Int J Environ Res Public Health. 2020; 17: 9509. Int J Environ Res Public Health. 2021; 18(19): 10143.

Hallmer F, Bjarnadottir O, Götrick B, Malmström P, Andersson G. Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020;130(3):252–7.

Article  PubMed  Google Scholar 

Petrovic M, Jelovac DB, Antic S, Antunovic M, Lukic N, Sabani M, et al. Medication-related osteonecrosis of the jaws: two center retrospective cohort studies. Biomed Res Int. 2019;18(2019):8345309.

Google Scholar 

Jung S, Kim J, Park JH, Kim KY, Kim HJ, Park W. A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients. Sci Rep. 2022;12(1):8641.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Milosavljević M, Jovanović M, Folić M, Živić M, Zdravković D, Veličković S, et al. Possible association of methotrexate use with osteonecrosis of the jaw: systematic review. J Stomatol Oral Maxillofac Surg. 2022;123(5):e458–63.

Article  PubMed  Google Scholar 

Owosho AA, Liang STY, Sax AZ, Wu K, Yom SK, Huryn JM, et al. Medication-related osteonecrosis of the jaw (MRONJ): an update on the Memorial Sloan Kettering Cancer Center (MSKCC) experience and the role of Pre-medication Dental Evaluation in the prevention of MRONJ. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125(5):440–5.

Article  PubMed  PubMed Central  Google Scholar 

Decaux J, Magremanne M. Medication-related osteonecrosis of the jaw related to epacadostat and pembrolizumab. J Stomatol Oral Maxillofac Surg. 2020;121(6):740–2.

Article  CAS  PubMed